Panacea Biotech Fact Sheet, Panacea Biotech Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Fact Sheet    (PANB)

Here is the latest financial fact sheet of Panacea Biotech. For more details, see the Panacea Biotech quarterly results and Panacea Biotech share price and chart. For a sector overview, read our pharmaceuticals sector report.

PANACEA BIOTECH Price History

Price Rs 141.9
Mkt Cap Rs m 8,688
Vol '000 0.7
P/E X 11.7
P/CF X -49.1
EPS (TTM) Rs 12.1
% ch % 2.9
No. of shares m 61.25
% ch week % 0.3
% ch 1-mth % -4.2
% ch 12-mth % -6.5
52 week H/L Rs 219.0/116.0
(As on Oct 24, 2019 10:35:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PANACEA BIOTECH Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
PANACEA BIOTECH EQUITY SHARE DATA
High Rs149219183178364 
Low Rs82958486129 
Sales per share (Unadj.) Rs84.1112.2106.688.896.8 
Earnings per share (Unadj.) Rs-18.3-17.4-3.0-6.7-12.4 
Diluted earnings per shareRs-18.3-17.4-3.0-6.7-12.4 
Cash flow per share (Unadj.) Rs-6.7-6.49.04.4-2.9 
Dividends per share (Unadj.) Rs00000 
Adj. dividends per shareRs0.000.000.000.000.00 
Dividend yield (eoy) %00000 
Book value per share (Unadj.) Rs83.774.365.958.150.4 
Adj. book value per shareRs83.774.365.958.150.4 
Shares outstanding (eoy) m61.2561.2561.2561.2561.25 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x1.41.41.31.52.5 
Avg P/E ratio x-6.3-9.0-44.7-19.8-19.9 
P/CF ratio (eoy) x-17.2-24.514.829.9-86.4 
Price / Book Value ratio x1.42.12.02.34.9 
Dividend payout %00000 
Avg Mkt Cap Rs m7,0749,6078,1718,07915,101 
No. of employees `0002.82.72.52.32.5 
Total wages/salary Rs m1,4491,3601,4201,4811,516 
Avg. sales/employee Rs Th1,874.12,537.62,613.42,406.12,401.9 
Avg. wages/employee Rs Th527.0502.1568.3655.1614.2 
Avg. net profit/employee Rs Th-407.7-393.3-73.2-180.8-307.9 
PANACEA BIOTECH INCOME DATA
Net Sales Rs m5,1546,8726,5315,4405,928 
Other income Rs m10028520446682 
Total revenues Rs m5,2547,1576,7345,9066,010 
Gross profit Rs m-7664391,117624845 
Depreciation Rs m711672733680585 
Interest Rs m1,5031,0451,2731,0091,006 
Profit before tax Rs m-2,881-994-686-599-664 
Minority Interest Rs m11182300 
Prior Period Items Rs m-6-58232 
Extraordinary Inc (Exp) Rs m1,7710497770 
Tax Rs m173119-11099 
Profit after tax Rs m-1,121-1,065-183-409-760 
Gross profit margin %-14.96.417.111.514.3 
Effective tax rate %-0.6-3.1-2.818.3-14.9 
Net profit margin %-21.8-15.5-2.8-7.5-12.8 
PANACEA BIOTECH BALANCE SHEET DATA
Current assets Rs m3,8105,2574,9915,3345,603 
Current liabilities Rs m8,3657,0604,6575,8816,910 
Net working cap to sales %-88.4-26.25.1-10.1-22.0 
Current ratio x0.50.71.10.90.8 
Inventory Days Days156165172212206 
Debtors Days Days6752699584 
Net fixed assets Rs m14,48012,99812,32110,3689,941 
Share capital Rs m6161616161 
"Free" reserves Rs m9034,4883,9743,4963,026 
Net worth Rs m5,1274,5494,0363,5573,087 
Long term debt Rs m5,8327,2307,8577,1415,707 
Total assets Rs m19,43319,30518,03018,00116,076 
Interest coverage x-0.900.50.40.3 
Debt to equity ratio x1.11.61.92.01.8 
Sales to assets ratio x0.30.40.40.30.4 
Return on assets %2.0-0.16.03.31.5 
Return on equity %-21.9-23.4-4.5-11.5-24.6 
Return on capital %3.60.19.34.63.9 
Exports to sales %24.530.936.033.724.0 
Imports to sales %10.220.49.514.317.5 
Exports (fob) Rs m1,2642,1252,3481,8321,424 
Imports (cif) Rs m5251,3996197801,040 
Fx inflow Rs m1,5392,3992,6981,9981,600 
Fx outflow Rs m9421,6739258981,131 
Net fx Rs m5977261,7731,101469 
PANACEA BIOTECH CASH FLOW
From Operations Rs m 599 372 907 1,307 1,180 
From Investments Rs m -438 -374 164 -258 553 
From Financial Activity Rs m -303 -7 -1,174 -1,070 -1,644 
Net Cashflow Rs m -141 -9 -103 -21 90 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 74.5%
Foreign collaborators 0.0%
Indian inst/Mut Fund 0.6%
FIIs 1.3%
ADR/GDR 0.0%
Free float 23.6%
Shareholders 10,259
Pledged promoter(s) holding 35.1%
 

Company Information

REGD OFF Ambala - Chandigarh Highway, Lalru, Punjab - 140 501
E-MAIL companysec@panaceabiotec.com WEB www.panaceabiotec.com
TELEPHONE (011) 4157 8024 FAX (011) 4167 9070
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Skyline Financial, D-153 A, Ist Flr., Okhla Indl. Area, Phase-I, New Delhi-20
AUDITOR S. R. Batliboi & Co.
CHM: Soshil Kumar Jain COMP SEC: Vinod Goel (GM-Legal) YEAR OF INC: 1985 BSE CODE: 531349 FV (Rs): 1 DIV YIELD (%): -

Read: PANACEA BIOTECH 2017-18 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   ELDER PHARMA  DISHMAN PHARMA  ALEMBIC LTD  INDOCO REMEDIES  DIVIS LABORATORIES  

Compare PANACEA BIOTECH With:   ELDER PHARMA  DISHMAN PHARMA  ALEMBIC LTD  INDOCO REMEDIES  DIVIS LABORATORIES  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Strong; HCL Tech and Tech Mahindra Top Gainers(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.6% while the Hang Seng is up 0.4%.

Views on news

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

My Top 10 Stocks for Accelerated Profits

Oct 18, 2019

Equitymaster's co-head of research and editor of Microcap Millionaires, Rahul Shah, talks to us about his market-beating system and his 10 best stocks to buy now. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS